AbbVie, CytomX to co-develop Probody drug conjugates
Executive Summary
In its third cancer deal in two days, AbbVie Inc. is now partnering with CytomX Therapeutics Inc. to co-develop and co-commercialize Probody drug conjugates against CD71, or transferrin receptor 1 (TfR1).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice